1. CLIC1 Expression in Skin Biopsies from Patients With Rheumatoid and Psoriatic Arthritis as a Potential Tool to Predict Therapy Response
- Author
-
Anca Maria Cimpean, Claudiu Avram, Ovidiu Simion Cotoi, Amalia Raluca Ceausu, Monica Chis, Liliana Bordean, and Marius Raica
- Subjects
Cancer Research ,medicine.medical_specialty ,Biopsy ,Arthritis ,Inflammation ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Arthritis, Rheumatoid ,Psoriatic arthritis ,Chloride Channels ,Internal medicine ,Humans ,Medicine ,Skin ,Pharmacology ,medicine.diagnostic_test ,biology ,business.industry ,Arthritis, Psoriatic ,C-reactive protein ,medicine.disease ,Methotrexate ,Rheumatoid arthritis ,Erythrocyte sedimentation rate ,biology.protein ,medicine.symptom ,business ,Vasculitis ,Research Article ,medicine.drug - Abstract
Background/Aim: Chloride intracellular channel protein 1 (CLIC1) activates inflammasomes in rheumatoid (RA) and psoriatic (PsA) arthritis. We studied CLIC1 expression in RA and PsA patients’ skin with vasculitis and its variability depending on the therapy used. Materials and Methods: CLIC1 immunoexpression was evaluated in the vascular (CLIC1-V) and stromal (CLIC1-S) compartments of the RA and PsA skin biopsies of patients treated with methotrexate (MTX), leflunomid (LFN), corticotherapy (CT), or biological therapies. Results: MTX significantly reduced CLIC1-S expression (p=0.016), whereas LFN decreased CLIC1-V (p
- Published
- 2021
- Full Text
- View/download PDF